ArticleCrohn's & colitis 3602026

Serum leucine-rich α-2-glycoprotein and monocyte chemoattractant protein-1 as novel biomarkers for predicting vedolizumab response in patients with ulcerative colitis.

Takeo Yoshihara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.